Yes, in spite of the following operational and fundamental achievements by the company, as detailed on an announcement on 26th Feb:
1. Record YTD FY24 revenues with a profit for the period; 2. Record quarterly research sales in Q1 FY24; 3. Record Q1 FY24 sales increase - 143% YOY (excluding clinical trials); 4. Record annual clinical trial revenues for FY24; 5. The largest clinical trial contract in the Company’s history ($8m+); 6. Cash of $7.8m, plus the $6m available under the C2V Funding Commitment Agreement 7. Building of chip inventory of 40,370 units (+ additional pending chip orders) for the production of the CONNEQT Pulse; 8. Pre-launch order pipeline for the CONNEQT Pulse of >$USD500,000; 9. Trial production underway for CONNEQT Pulse in anticipation of commercial launch in H1 2024; 10. A new agreement with SunTech Medical for Oscar 2 ABPM which expands the Company’s sales territories and revenue opportunities for this device; 11. Completion of the Blumio acquisition; 12. Successful clinical validation of the CONNEQT Band technology (as a pre-cursor to regulatory approval being sought - anticipated to be July 2024); 13. A digital content partnership with American Heart Association (AHA); 14. National Institutes of Health (USA) recognition and award for the CONNEQT product suite including the CONNEQT Pulse and our wearable technology; 15. Medtech Innovator finalist for the CONNEQT Pulse – one of the most prestigious global medtech device awards; and 16. American Heart Association 2023 Healthtech finalist for the CONNEQT Pulse.
The question that needs to be asked is who is nurturing the negative sentiment around a $20m company that has achieved all of this, and what is their objective?
CDX Price at posting:
7.6¢ Sentiment: Buy Disclosure: Held
